Biomarker & Intervention Discovery

Fibromyalgia

This page lists 6 druggable gene targets, 34 approved or trial-tested drug candidates and 15 recent clinical trials for Fibromyalgia, with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

Plain-language summary → New Treatments for Fibromyalgia (2026): Drugs in Trials

US DALYs4.08MWHO GHE 2021 · all ages
Global DALYs45.69MWHO GHE 2021 · worldwide
US mortality12.5K deaths/yrWHO GHE 2021
Global mortality110.0K deaths/yrWHO GHE 2021 · worldwide
NIH funding$15MFY2025 · RCDC estimate
Funding levelSeverely Underfunded
Spontaneous remissionPartial spontaneous improvement in ~25-30% over 5 years; complete resolution without treatment rare; chronic…
Best-intervention remissionMultimodal approach (aerobic exercise + CBT + sleep optimisation): most effective combination — 50-60% significant…
Gap sizeLarge — pharmacotherapy is modestly effective; exercise is the most effective single intervention but chronically…
Primary barrierframing/practice
Full remission profile →
Research Tracker Chronic Disease Interventions Fibromyalgia

Remission & chronicity

Spontaneous remission
Partial spontaneous improvement in ~25-30% over 5 years; complete resolution without treatment rare; chronic fluctuating course in majority; central sensitisation often persists
Best-intervention remission
Multimodal approach (aerobic exercise + CBT + sleep optimisation): most effective combination — 50-60% significant improvement; duloxetine: 50% pain response in 43% vs 29% placebo; milnacipran: similar; pregabalin: 50% pain response 38-50%; low-dose naltrexone (LDN): 30% improvement in open-label studies
Gap size
Large — pharmacotherapy is modestly effective; exercise is the most effective single intervention but chronically underused as 'too painful'; disease is often dismissed
Primary barrier
framing/practice
Fibromyalgia was dismissed as non-organic by mainstream medicine for decades; this has resulted in: delayed diagnosis (mean 5 years), inappropriate investigations, ineffective treatments (opioids in particular), and under-referral to physiotherapy and psychological therapies; the 2010 ACR criteria removed tender point requirement and improved diagnosis

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

GRIN1 183GRIN2B 238SCN9A 271SLC6A2 269SLC6A4 224TRPV1 160

GRIN1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
COMPOUND 53 [PMID: 33038794] ↑ activates Mechanistic DGIdb
PAREGORIC ? unclear Mechanistic DGIdb
STING AGONIST 2 ↑ activates Mechanistic DGIdb
LATREPIRDINE ? unclear Mechanistic DGIdb
CNS-5161 ↓ inhibits Mechanistic DGIdb
MEMANTINE HYDROCHLORIDE ~ modulates Mechanistic DGIdb
LANICEMINE ↓ inhibits Mechanistic DGIdb
ULEVOSTINAG ↑ activates Mechanistic DGIdb
ELIPRODIL ? unclear Mechanistic DGIdb
NBQX ? unclear Mechanistic DGIdb
RAPASTINEL ? unclear Mechanistic DGIdb
DEXANABINOL ? unclear Mechanistic DGIdb
NEBOGLAMINE ~ modulates Mechanistic DGIdb
HALOPERIDOL DECANOATE ? unclear Mechanistic DGIdb
ORPHENADRINE ? unclear Mechanistic DGIdb
GW468816 ↓ inhibits Mechanistic DGIdb
ACAMPROSATE CALCIUM ↓ inhibits Mechanistic DGIdb
AMANTADINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
H-151 ↓ inhibits Mechanistic DGIdb
D-SERINE ? unclear Mechanistic DGIdb
AZD8108 ↓ inhibits Mechanistic DGIdb
KETAMINE HYDROCHLORIDE ~ modulates Mechanistic DGIdb
DELUCEMINE ↓ inhibits Mechanistic DGIdb
EVT-101 ↓ inhibits Mechanistic DGIdb
MSA-2 ↑ activates Mechanistic DGIdb
ESKETAMINE HYDROCHLORIDE ? unclear Mechanistic DGIdb
2'3'-CGAMP ↑ activates Mechanistic DGIdb
COMPOUND 40 [PMID: 33470814] ↑ activates Mechanistic DGIdb
PHILANTHOTOXIN 343 ? unclear Mechanistic DGIdb
FELBAMATE ↓ inhibits Mechanistic DGIdb
INDANTADOL ↓ inhibits Mechanistic DGIdb
STING AGONIST 3 ↑ activates Mechanistic DGIdb
ORPHENADRINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
CYCLOSERINE ? unclear Mechanistic DGIdb
RADIPRODIL ↓ inhibits Mechanistic DGIdb
PERZINFOTEL ↓ inhibits Mechanistic DGIdb
ESKETAMINE ~ modulates Mechanistic DGIdb
ADU-S100 ↑ activates Mechanistic DGIdb
RALFINAMIDE ↓ inhibits Mechanistic DGIdb
SNX281 ↑ activates Mechanistic DGIdb

Showing top 40 of 183 agents ranked by evidence tier.

GRIN2B

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
DIMIRACETAM ? unclear Mechanistic DGIdb
KETAMINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
PERZINFOTEL ↓ inhibits Mechanistic DGIdb
[3H]CGP39653 ↓ inhibits Mechanistic DGIdb
PHENCYCLIDINE ↓ inhibits Mechanistic DGIdb
DEXANABINOL ? unclear Mechanistic DGIdb
RAPASTINEL ↑ activates Mechanistic DGIdb
DELUCEMINE ↓ inhibits Mechanistic DGIdb
AMANTADINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
RISLENEMDAZ ↓ inhibits Mechanistic DGIdb
ORPHENADRINE CITRATE ↓ inhibits Mechanistic DGIdb
ELIPRODIL ? unclear Mechanistic 13.0 nM (Ki) DGIdb
INDANTADOL ? unclear Mechanistic DGIdb
SEVOFLURANE ? unclear Mechanistic DGIdb
SAGE-718 ~ modulates Mechanistic DGIdb
L689560 ↓ inhibits Mechanistic DGIdb
ONFASPRODIL ~ modulates Mechanistic DGIdb
HOMOQUINOLINIC ACID ↑ activates Mechanistic DGIdb
NEBOGLAMINE ~ modulates Mechanistic DGIdb
DIZOCILPINE ↓ inhibits Mechanistic DGIdb
LY233053 ↓ inhibits Mechanistic DGIdb
GLYCINE ↑ activates Mechanistic DGIdb
ESKETAMINE ~ modulates Mechanistic DGIdb
[3H]CGP61594 ↓ inhibits Mechanistic DGIdb
ORPHENADRINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
[3H]MDL105519 ↓ inhibits Mechanistic DGIdb
RADIPRODIL ? unclear Mechanistic DGIdb
NBQX ? unclear Mechanistic DGIdb
SEMAPIMOD ↓ inhibits Mechanistic DGIdb
SELFOTEL ↓ inhibits Mechanistic DGIdb
SERINE, D- ↑ activates Mechanistic DGIdb
COMPOUND 18C [PMID: 25901531] ↓ inhibits Mechanistic DGIdb
AZD8108 ↓ inhibits Mechanistic DGIdb
[3H]L689560 ↓ inhibits Mechanistic DGIdb
TRAXOPRODIL ↓ inhibits Mechanistic 74.0 nM (IC50) DGIdb
HALOPERIDOL DECANOATE ? unclear Mechanistic DGIdb
N1-DANSYL-SPERMINE ↓ inhibits Mechanistic DGIdb
[3H]D-ASPARTIC ACID ↑ activates Mechanistic DGIdb
NERAMEXANE ? unclear Mechanistic DGIdb
NVP-AAM077 ↓ inhibits Mechanistic DGIdb

Showing top 40 of 238 agents ranked by evidence tier.

SCN9A

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
MERETHOXYLLINE PROCAINE ↓ inhibits Mechanistic DGIdb
ETIDOCAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
FOSPHENYTOIN ↓ inhibits Mechanistic DGIdb
VERATRIDINE ↑ activates Mechanistic DGIdb
ORPHENADRINE CITRATE ↓ inhibits Mechanistic DGIdb
PHENACEMIDE ↓ inhibits Mechanistic DGIdb
LACOSAMIDE ↓ inhibits Mechanistic DGIdb
VIXOTRIGINE ↓ inhibits Mechanistic DGIdb
DSP-2230 ↓ inhibits Mechanistic DGIdb
SAXITOXIN ↓ inhibits Mechanistic DGIdb
ESLICARBAZEPINE ACETATE ↓ inhibits Mechanistic DGIdb
SAFINAMIDE ? unclear Mechanistic DGIdb
LIDOCAINE ↓ inhibits Mechanistic DGIdb
RILUZOLE ↓ inhibits Mechanistic DGIdb
ROPIVACAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
FUNAPIDE ↓ inhibits Mechanistic DGIdb
DYCLONINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
EVENAMIDE ↓ inhibits Mechanistic DGIdb
PROPOFOL ? unclear Mechanistic DGIdb
AM-6120 ↓ inhibits Mechanistic DGIdb
RG7893 ↓ inhibits Mechanistic DGIdb
RG6029 ↓ inhibits Mechanistic DGIdb
QUINIDINE SULFATE ↓ inhibits Mechanistic DGIdb
ZONISAMIDE ↓ inhibits Mechanistic DGIdb
NERISPIRDINE ↓ inhibits Mechanistic DGIdb
RALFINAMIDE ↓ inhibits Mechanistic DGIdb
DS-1971A ↓ inhibits Mechanistic DGIdb
HEXYLCAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
MEPIVACAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
PROCAINAMIDE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
PROPAFENONE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
LIDOCAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
QUINIDINE GLUCONATE ↓ inhibits Mechanistic DGIdb
PRILOCAINE ↓ inhibits Mechanistic DGIdb
ETHOTOIN ↓ inhibits Mechanistic DGIdb
PF-05089771 ↓ inhibits Mechanistic DGIdb
DICHLOROBENZYL ALCOHOL ↓ inhibits Mechanistic DGIdb
RANOLAZINE ? unclear Mechanistic DGIdb
PRILOCAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
ORPHENADRINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb

Showing top 40 of 271 agents ranked by evidence tier.

SLC6A2

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
TESOFENSINE ↓ inhibits Mechanistic DGIdb
PHENMETRAZINE ? unclear Mechanistic DGIdb
VENLAFAXINE ? unclear Mechanistic 1060.0 nM (Kd) DGIdb
SIBUTRAMINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
DEXMETHYLPHENIDATE ↓ inhibits Mechanistic DGIdb
TRIMIPRAMINE ? unclear Mechanistic DGIdb
CLOMIPRAMINE ? unclear Mechanistic DGIdb
GUANADREL SULFATE ? unclear Mechanistic DGIdb
TAPENTADOL HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
LISDEXAMFETAMINE DIMESYLATE ? unclear Mechanistic DGIdb
PROTRIPTYLINE ? unclear Mechanistic DGIdb
DESVENLAFAXINE SUCCINATE ↓ inhibits Mechanistic DGIdb
ATOMOXETINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
IOBENGUANE I-123 ? unclear Mechanistic DGIdb
SURONACRINE MALEATE ? unclear Mechanistic DGIdb
REBOXETINE ↓ inhibits Mechanistic 1.1 nM (Ki) DGIdb
BICIFADINE ↓ inhibits Mechanistic DGIdb
DOXEPIN HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
LIAFENSINE ↓ inhibits Mechanistic DGIdb
ORPHENADRINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
DULOXETINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
DASOTRALINE ↓ inhibits Mechanistic DGIdb
DESIPRAMINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
METHYLPHENIDATE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
AMITIFADINE ↓ inhibits Mechanistic DGIdb
NEFAZODONE ? unclear Mechanistic 360.0 nM (Kd) DGIdb
AMITIFADINE HYDROCHLORIDE ? unclear Mechanistic DGIdb
DEXTROAMPHETAMINE SULFATE ? unclear Mechanistic DGIdb
TYROSINE HYDROXYLASE INHIBITOR ? unclear Mechanistic DGIdb
NORTRIPTYLINE ? unclear Mechanistic 6.3 nM (Ki) DGIdb
MAPROTILINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
ST. JOHN'S WORT ? unclear Mechanistic DGIdb
DEXTROAMPHETAMINE SACCHARATE ? unclear Mechanistic DGIdb
AMOXAPINE ↓ inhibits Mechanistic DGIdb
PHENDIMETRAZINE ↓ inhibits Mechanistic DGIdb
PHENYLPROPANOLAMINE HYDROCHLORIDE ? unclear Mechanistic DGIdb
BUPROPION HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
BETHANIDINE ? unclear Mechanistic DGIdb
TRAMADOL ? unclear Mechanistic DGIdb
MILNACIPRAN ? unclear Mechanistic DGIdb

Showing top 40 of 269 agents ranked by evidence tier.

SLC6A4

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CENTANAFADINE ↓ inhibits Mechanistic DGIdb
METHAMPHETAMINE ↓ inhibits Mechanistic DGIdb
VENLAFAXINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
LUMATEPERONE ↓ inhibits Mechanistic DGIdb
TIANEPTINE ? unclear Mechanistic DGIdb
IMIPRAMINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
ONDANSETRON HYDROCHLORIDE ? unclear Mechanistic DGIdb
PEGINTERFERON ALFA-2B ? unclear Mechanistic DGIdb
DEXFENFLURAMINE ? unclear Mechanistic DGIdb
BUPROPION HYDROCHLORIDE ? unclear Mechanistic DGIdb
CITALOPRAM ↓ inhibits Mechanistic 1.6 nM (Ki) DGIdb
TRIMIPRAMINE ? unclear Mechanistic DGIdb
VENLAFAXINE ? unclear Mechanistic 8.9 nM (Kd) DGIdb
DISULFIRAM ? unclear Mechanistic DGIdb
CHLORPHENTERMINE HYDROCHLORIDE ? unclear Mechanistic DGIdb
PROTRIPTYLINE ? unclear Mechanistic DGIdb
MILNACIPRAN HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
CLOMIPRAMINE ? unclear Mechanistic 70.0 nM (IC50) DGIdb
NORTRIPTYLINE ? unclear Mechanistic DGIdb
DAPOXETINE ↓ inhibits Mechanistic DGIdb
AMITRIPTYLINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
TEDATIOXETINE ↓ inhibits Mechanistic DGIdb
TRAZODONE ↓ inhibits Mechanistic DGIdb
SERTRALINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
EVODIAMINE ? unclear Mechanistic DGIdb
PSEUDOEPHEDRINE ? unclear Mechanistic DGIdb
FLUOXETINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
SIBUTRAMINE ? unclear Mechanistic DGIdb
TRAMADOL ? unclear Mechanistic DGIdb
VORTIOXETINE HYDROBROMIDE ↓ inhibits Mechanistic DGIdb
BL-1021 ? unclear Mechanistic DGIdb
DOXEPIN HYDROCHLORIDE ? unclear Mechanistic DGIdb
DOTHIEPIN ↓ inhibits Mechanistic DGIdb
DEXTROMETHORPHAN POLISTIREX ? unclear Mechanistic DGIdb
DESIPRAMINE ? unclear Mechanistic DGIdb
PHENTERMINE RESIN ? unclear Mechanistic DGIdb
NORTRIPTYLINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
MONOAMINE OXIDASE INHIBITOR ? unclear Mechanistic DGIdb
MILNACIPRAN ? unclear Mechanistic DGIdb
RIBAVIRIN ? unclear Mechanistic DGIdb

Showing top 40 of 224 agents ranked by evidence tier.

TRPV1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
STREPTOZOCIN ? unclear Mechanistic DGIdb
BENZYL ISOTHIOCYANATE ? unclear Mechanistic DGIdb
ACETAMINOPHEN ↑ activates Mechanistic DGIdb
POLYGODIAL ? unclear Mechanistic DGIdb
PROPOFOL ? unclear Mechanistic DGIdb
SAF312 ↓ inhibits Mechanistic DGIdb
GRC-15300 ? unclear Mechanistic DGIdb
AZD1386 ↓ inhibits Mechanistic DGIdb
TIVANISIRAN ↓ inhibits Mechanistic DGIdb
MAVATREP ↓ inhibits Mechanistic DGIdb
MR-1817 ↓ inhibits Mechanistic DGIdb
FERRUGINENE B ? unclear Mechanistic DGIdb
CAPSAICIN ↑ activates Mechanistic 19.95 nM (EC50) DGIdb
RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN ? unclear Mechanistic DGIdb
PHENETHYLISOTHIOCYANATE ? unclear Mechanistic DGIdb
VOACANGINE ? unclear Mechanistic DGIdb
RESINIFERATOXIN ↑ activates Mechanistic 23.1 nM (Ki) DGIdb
DWP05195 ↓ inhibits Mechanistic DGIdb
XEN-D0501 ↓ inhibits Mechanistic DGIdb
PAC-14028 ↓ inhibits Mechanistic DGIdb
SB-705498 ↓ inhibits Mechanistic DGIdb
MASOPROCOL ? unclear Mechanistic DGIdb
ALLYL ISOTHIOCYANATE ? unclear Mechanistic DGIdb
NGD-8243 ↓ inhibits Mechanistic DGIdb
GRC-6211 ↓ inhibits Mechanistic DGIdb
RESERPINE ? unclear Mechanistic DGIdb
NABIXIMOLS ? unclear Mechanistic DGIdb
A425619 ? unclear Mechanistic DGIdb
PHE377 ↓ inhibits Mechanistic DGIdb
ANTISENSE OLIGONUCLEOTIDES ? unclear Mechanistic DGIdb
WORTMANNIN ? unclear Mechanistic DGIdb
JTS-653 ↓ inhibits Mechanistic DGIdb
LEVODOPA ? unclear Mechanistic DGIdb
AMG517 ↓ inhibits Mechanistic DGIdb
CAPSAZEPINE ? unclear Mechanistic 120.0 nM (Ki) DGIdb
ZUCAPSAICIN ↑ activates Mechanistic DGIdb
INDOMETHACIN ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL191534 ? unclear Mechanistic DGIdb
ABT-102 ↓ inhibits Mechanistic DGIdb
ISOPROPYL ISOTHIOCYANATE ? unclear Mechanistic DGIdb

Showing top 40 of 160 agents ranked by evidence tier.

Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Fibromyalgia: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

Mechanism Study of Yangyin Roujin Formula in the Treatment of Fibromyalgia Syndrome Recruiting
NCT07736144 Phase: N/A Started: 2025-01-01

This prospective randomized, double-blind, controlled clinical trial is designed to address the current challenges in the clinical management of fibromyalgia (FM). Investigators adopt Yangyin Roujin Formula, an empirical herbal prescription used in routine clinical practice, to evaluate its comprehe...

Impact of Post-Traumatic Stress Disorder Treatment by Reconsolidation Therapy on Fibromyalgia Syndrome Completed
NCT04950426 Phase: 2 Started: 2021-08-13

The aim of the study is to demonstrate a significant improvement in quality of life specific to patients with fibromyalgia syndrome in patients with fibromyalgia syndrome with comorbid posttraumatic stress disorder, treated with reconsolidation blockade. Patients receive a treatment with propranolol...

Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design Recruiting
NCT07398417 Phase: 3 Started: 2026-01-14

The study is a Phase 3, double-blind, placebo-controlled, randomized withdrawal study to assess the efficacy and safety of AXS-14 in the management of fibromyalgia.

The Efficacy and Safety of Pregabalin Combined With Venlafaxine in Patients With Fibromyalgia Recruiting
NCT07186751 Phase: N/A Started: 2025-09-20

Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread pain, fatigue, and emotional disorders. Its onset is related to factors such as central sensitization and imbalance of neurotransmitters. The current mainstream treatments include pregabalin, but the efficacy of pregabalin is l...

MDMA-assisted Therapy for Fibromyalgia Recruiting
NCT06066853 Phase: Early 1 Started: 2026-09-15

Fibromyalgia is a debilitating chronic pain disorder. Based on prior research with MDMA, it can be hypothesized MDMA-assisted therapy in fibromyalgia patients may increase the range of positive emotions, interpersonal trust, and heighten the state of empathic rapport that can lead to an enhanced pat...

Vagus Nerve Stimulation in Fibromyalgia Completed
NCT06237595 Phase: N/A Started: 2023-09-30

Vagus nerve stimulation is thought to reduce sympathetic nerve outflow and so can improve sympathetic hyperactivity in fibromyalgia patients. We aimed in the current study, to evaluate the effect of the cervical transcutaneous vagus nerve stimulation in comparison to conventional medical treatment i...

Yishen Shujin Decoction for Fibromyalgia Syndrome Recruiting
NCT07555691 Phase: N/A Started: 2025-03-01

This 24-week prospective study (12-week intervention + 12-week follow-up) is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the therapeutic effects of YishenShujin Decoction, a clinically established herbal prescription, in patients with fibromyalgia (FM). The pri...

Study on the Efficacy and Safety of Tongluo Kaibi Tablets in the Treatment of Fibromyalgia Syndrome Completed
NCT07708948 Phase: 4 Started: 2024-01-01

Fibromyalgia is a chronic, disabling musculoskeletal pain disorder. Pregabalin is the sole pharmaceutical agent approved for the treatment of fibromyalgia in China. Tongluo Kaibi Tablet, an approved proprietary Chinese medicine with collaterals-dredging and blood-activating effects, has demonstrated...

A Clinical Study of ONO-1110 in Patients With Fibromyalgia Completed
NCT06752590 Phase: 2 Started: 2025-03-26

To Evaluate the Efficacy and Safety of ONO-1110 in Patients with Fibromyalgia

The Efficacy and Safety of Pregabalin and Mirogabalin in Patients With Fibromyalgia Recruiting
NCT07157852 Phase: N/A Started: 2025-09-05

Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread pain, fatigue, and emotional disorders. Its onset is related to factors such as central sensitization and imbalance of neurotransmitters. The current mainstream treatments include pregabalin, but the efficacy of pregabalin is l...

The Potential Application of Plasma-Activated Water in Fibromyalgia Patients Recruiting
NCT07659236 Phase: N/A Started: 2024-07-01

Fibromyalgia is a chronic syndrome characterized by widespread pain that is commonly observed in pain, rheumatology, or rehabilitation clinics. Previous studies have suggested a fibromyalgia prevalence rate of approximately 2%. Currently, evidence shows that fibromyalgia might be partially associate...

Adding Neuromodulation Technique to Cognitive Behavior Therapy on Fibromyalgia in Postmenopausal Women Completed
NCT07533487 Phase: N/A Started: 2022-09-01

The goal of this clinical trial is to investigate the effect of adding transcutaneous electrical nerve stimulation to cognitive behavior therapy on fibromyalgia in postmenopausal women. The study aims to answer whether there would be an effect of adding TENS to cognitive behavior therapy (CBT) and m...

Effectiveness of Oral Magnesium Supplementation in Fibromyalgia Patients Not Responding to Standard Treatment Recruiting
NCT07585045 Phase: N/A Started: 2026-04-16

Fibromyalgia is a complex widespread pain disorder. OBJECTIVES To evaluate the effectiveness of oral magnesium supplementation in reducing symptom severity among fibromyalgia patients who have not responded to standard treatment, using validated scoring systems such as the Fibromyalgia Impact Questi...

Probiotics for Cognitive Function, Pain, and Quality of Life in People With Fibromyalgia Completed
NCT07582965 Phase: N/A Started: 2020-11-27

Fibromyalgia is a complex chronic disorder in which emerging evidence suggests a relevant role of the gut microbiota in modulating physiological processes through the gut-brain axis. In this context, probiotics have been proposed as a potential therapeutic strategy for symptom management in fibromya...

The Efficacy and Safety of Short Term S-ketamine Infusion as an Adjunctive Therapy in Patients With Fibromyalgia Recruiting
NCT07230171 Phase: N/A Started: 2025-09-15

Fibromyalgia is a chronic pain syndrome where current medications have limited efficacy and a slow onset of action. Esketamine shows potential as a rapid-acting analgesic, but previous low-dose studies failed to demonstrate long-term benefits. The efficacy of higher-dose ESK as an adjunctive therapy...

Agents Found By Disease-Level Search

Searched directly from “Fibromyalgia” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 6-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

34 agents shown (approved or with trial evidence) — 31 not found by the gene-target search above.

Esreboxetine

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00752505 NCT00752505

Dry needlingNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT05320601 NCT06023836

milnacipran

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT01173055 NCT01234675

pregabalinNOT in gene-target list

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00151489 NCT00883740

Pregabalin capsuleNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT07708948 NCT03890133

Capsaicin Patch 8% or 0.1% Capsaicin CreamNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03464292

bupivacaine and acupunctureNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00635037

Naltrexone PillNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04270877

Electrical Dry Needling (EDN)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07148635

ABMNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05905159

Tramadol hydrochlorideNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00766675

Acetaminophen

Unknown · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00766675

Radial Extracorporeal Shockwave TherapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07593781

Radial Shockwave TherapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02760212

TrainPainNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04919525

Low Dose NaltrexoneNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02107014

AXS-14 (Esreboxetine)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07398417

Graston technique (IASTM)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06598826

ReSeT-FM interventionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03247348

Botulinum Toxin A InjectionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06899438

Prilocaine HCl % 2 injectable solutionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06899438

ESL 400 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01820585

ESL 800 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01820585

ESL 1200 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01820585

Xyrem®NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00423605

Saizen®NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00933686

TNX-102 SLNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02015234

QuetiapineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01458964

Pregabalin and venlafaxine concomitant therapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07230171

Esketamine plus pregabalin and venlafaxine concomitant therapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07230171

fibroDAO®NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05389761

Silymarin (LEGALON)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07293767

Diosmin / Hesperidin (Daflon)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07293767

Breathing ControlNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05773482

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.